cytisine
Cytisine, also known as baptitoxine, cytisinicline, or sophorine, is an alkaloid that occurs naturally in several plant genera, such as Laburnum and Cytisus of the family Fabaceae. It has been used medically to help with smoking cessation. It has been found effective in several randomized clinical trials, including in the United States and New Zealand, and is being investigated in additional trials in the United States and a non-inferiority trial in Australia in which it is being compared head-to-head with the smoking cessation aid varenicline. It has also been used entheogenically via mescalbeans by some Native American groups, historically in the Rio Grande Valley predating even peyote. — Wikipedia
Clinical trial activity
15 trials · 17 clinical orgs · 0 marketing orgs
Earliest trial started Aug 8, 2017 (NCT03268343)
Timeline
Indications
Approved for
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCytisine ↗
- WikipediaCytisinicline ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07274475 | N/A | Dec 1, 2025 | University of Toronto |
| NCT06832085 | Phase 4 | Apr 30, 2025 | University of Ottawa |
| NCT06945770 | N/A | May 1, 2024 | Ege University |
| NCT05729243 | Phase 4 | Feb 8, 2023 | University of Toronto |
| NCT05311085 | Phase 3 | May 6, 2022 | University of Auckland |
| NCT05102123 | Phase 2/Phase 3 (Phase 3) | Apr 1, 2022 | McMaster University |
| NCT04286295 | N/A | Mar 1, 2020 | University of Ottawa |
| NCT04126135 | Phase 3 | Oct 31, 2019 | Loma Linda University, Mongolian National University of Medical Sciences, Pfizer |
| NCT04015414 | Phase 3 | Sep 1, 2019 | Harvard University, University of Ljubljana, University of Zagreb |
| NCT03848208 | Phase 1 | Feb 28, 2019 | Achieve Life Sciences, Hospital da Prelada |
| NCT03709823 | Phase 2 | Nov 13, 2018 | Achieve Life Sciences, Los Angeles Clinical Trials |
| NCT03654105 | Phase 2 | Oct 31, 2018 | Mario Negri Institute, University of Milan |
| NCT03509948 | Phase 1 | Apr 27, 2018 | Achieve Life Sciences, Simbec-Orion |
| NCT03303911 | Phase 1/Phase 2 (Phase 2) | Oct 6, 2017 | Achieve Life Sciences, Simbec-Orion |
| NCT03268343 | Phase 1 | Aug 8, 2017 | Achieve Life Sciences, Simbec-Orion |
Organizations
Research & Development (17)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Achieve Life Sciences | For profit | 5 | 5 | 2 | 2017 |
| Simbec-Orion | For profit | 3 | 0 | 2 | 2017 |
| University of Ottawa | Academic/Hospital | 2 | 2 | 2 | 2020 |
| University of Toronto | Academic/Hospital | 2 | 2 | 2 | 2023 |
| Ege University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Hospital da Prelada | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Loma Linda University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Los Angeles Clinical Trials | For profit | 1 | 0 | 1 | 2018 |
| Mario Negri Institute | Academic/Hospital | 1 | 0 | 1 | 2018 |
| McMaster University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Mongolian National University of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Pfizer | For profit | 1 | 0 | 1 | 2019 |
| University of Auckland | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Ljubljana | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Milan | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Zagreb | Academic/Hospital | 1 | 1 | 1 | 2019 |